ProCE Banner Activity

Do We Need Prophylaxis for Pneumocystis jirovecii Pneumonia in Virologically Suppressed Patients?

Clinical Thought
Here’s my take on the need for prophylaxis for Pneumocystis jirovecii pneumonia in virologically suppressed patients, including discussion of dosing and choice of regimen when used.

Released: November 23, 2021

Expiration: November 22, 2022

No longer available for credit.

Share

Faculty

Roger Bedimo

Roger Bedimo, MD, MS, FACP

Associate Professor of Medicine
Division of Infectious Diseases
University of Texas Southwestern Medical Center
Section Chief
Division of Infectious Diseases
Department of Internal Medicine
VA North Texas Health Care System
Dallas, Texas

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Roger Bedimo, MD, MS, FACP

Associate Professor of Medicine
Division of Infectious Diseases
University of Texas Southwestern Medical Center
Section Chief
Division of Infectious Diseases
Department of Internal Medicine
VA North Texas Health Care System
Dallas, Texas

Roger Bedimo, MD, MS, FACP, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV and funds for research support from ViiV.